Standardizing Measurement of Tumor Mutational Burden Biomarkers
نویسندگان
چکیده
منابع مشابه
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
Immune checkpoint inhibitors targeting the PD-1 pathway have greatly changed clinical management of metastatic urothelial carcinoma and metastatic renal cell carcinoma. However, response rates are low, and biomarkers are needed to predict for treatment response. Immunohistochemical quantification of PD-L1 was developed as a promising biomarker in early clinical trials, but many shortcomings of ...
متن کاملStandardizing Patient Outcomes Measurement.
ffihe arc of history is increasingIL clear; health care is shifting focus from the volume of services delivered to the value created for patients, with "value" defined as the outcomes achieved relative to the costs.1 But progress has been slow and halting, partly because measurement of outcomes that matter to patients, aside from survival, remains limited. And for many conditions, death is a ra...
متن کاملTumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Immunotherapy induces durable responses in a subset of patients with cancer. High tumor mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors such as melanoma and non-small cell lung cancer (NSCLC). Our aim was to examine the relationship between TMB and outcome in diverse cancers treated with various immunotherapies. We reviewed data on 1,638 patients who had un...
متن کاملWhole-genome mutational burden analysis of three pluripotency induction methods
There is concern that the stresses of inducing pluripotency may lead to deleterious DNA mutations in induced pluripotent stem cell (iPSC) lines, which would compromise their use for cell therapies. Here we report comparative genomic analysis of nine isogenic iPSC lines generated using three reprogramming methods: integrating retroviral vectors, non-integrating Sendai virus and synthetic mRNAs. ...
متن کاملTumor Tissue-Based Biomarkers
Cancer Control 219 detailed diagnostic and prognostic categorization. Recently published gene expression and proteomic profiling data indicate new candidate molecules involved in melanoma pathogenesis, which are currently validated. This ongoing process of biomarker identification and validation results in a rapidly changing molecular view and classification of cutaneous malignancies, which hol...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Times
سال: 2020
ISSN: 0276-2234
DOI: 10.1097/01.cot.0000717724.61245.36